Results of estrogen receptor (ER) and progesterone receptor (PgR) ligandbinding assays
(LBAs) are strongly correlated with ER and PgR by immunohistochemistry (IHC). To …

PURPOSE Southwest Oncology Group (SWOG) protocol 8228 is a prospective trial
designed to investigate the prognostic significance of progesterone receptor (PgR) levels in …

Background: The importance of establishing hormone receptor status of tumors for the
treatment of women with hormone receptor-positive breast cancer has been emphasized …

Four hundred fifteen patients with metastatic breast cancer with known hormone receptor
status received primary treatment with tamoxifen. Measured values for the estrogen receptor …

Tamoxifen is one of the most effective treatments for breast cancer. Standard practice is to
select patients who are likely to respond to this therapy through the evaluation of estrogen …

The estrogen receptor (ER) assay has become a standard practice in the management of
advanced breast cancer. Tumors lacking ER respond infrequently to endocrine therapy …

This review presents our experience with the use of estrogen receptors (ER) and
progesterone receptors (PgR) in the prediction of response to endocrine therapy in stage IV …

PURPOSE: Immunohistochemistry (IHC) is a newer technique for assessing the estrogen
receptor (ER) status of breast cancers, with the potential to overcome many of the …

Breast cancer is often hormone responsive, since growth or regression of tumors can often
be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear …

Background: Changes in the receptor profile between primary and metastatic breast cancer
tissue have been suggested. The degree of hormone receptor discordance in archival …